Destiny Pharma PLC - Brighton, England-based clinical-stage biotechnology company focused on preventing life-threatening infections - Says Nigel Rudd will be returning as chair, effective immediately. He was chair of Destiny from 2010 to 2018, and led its flotation on the London AIM market.
Rudd's return follows the appointment of Chris Tovey as chief executive officer, and the return of interim CEO Debra Barker to her position as non-executive director.
Chair Nigel Rudd says: "It is with great pleasure that I can return to the company at such an exciting time, as we move towards the commercialisation of our products. Our recent market research is indicating that there is a blockbuster, USD2 billion plus opportunity with the XF-73 programme in the US alone. And our NTCD-M3 programme is phase 3 ready, with the clinical development and regulatory investment required, coming from our partner Sebela."
Current stock price: 34.15 pence
12-month change: down 8.9%
By Holly Beveridge, Alliance News reporter
Comments and questions to newsroom@alliancenews.com
Copyright 2023 Alliance News Ltd. All Rights Reserved.
Destiny Pharma. (DEST)